Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria

<p>REDWOOD CITY, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) […]</p>
<p>The post <a href="https://forextv.com/top-news/jasper-announces-first-patient-dosed-in-phase-1b-2a-clinical-study-of-briquilimab-in-chronic-spontaneous-urticaria/">Jasper Announces First Patient Dosed in Phase 1b/2a Clinical Study of Briquilimab in Chronic Spontaneous Urticaria</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>